SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Aug. 2, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the second quarter ended June 30, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, August 15, 2022. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time.
Conference call and webcast details:
Monday, August 15, 2022 @ 8:00am ET
Investor domestic dial-in: (800) 715-9871
Investor international dial-in: (646) 307-1963
Conference ID: 7693510
Live webcast link: https://ir.gracellbio.com/news-events/events-and-presentations
A replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days.
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CARTTM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-report-second-quarter-2022-financial-on-monday-august-15-2022-301597765.html
Source: Gracell Biotechnologies Inc. Related Stocks: NASDAQ:GRCL
- Gracell Biotechnologies Schedules Clinical Update Call After EHA2022
- Gracell Biotechnologies to Participate in BTIG 2022 Biotechnology Conference
- Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
- Daqo New Energy to Announce Unaudited Results for the Second Quarter of 2022 on August 3, 2022
- Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer
- Tarena to Report First Quarter 2022 Financial Results on May 17, 2022
- Greenland Technologies to Report First Quarter 2022 Unaudited Financial Results on Monday, May 16, 2022
- Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer
- iClick Interactive to Report its Unaudited First Quarter 2022 Financial Results on May 27, 2022